Ilyang Pharm advances to the global market with leukemia treatment, ‘Supect’

Ilyang Pharm(CEO Dong-yun Kim) attracted interest of the global market as announcing 3 results of the final clinical trial of the Asia’s first leukemia treatment, ‘Supect(generic name: radotinib).’

At the ‘57^th American Society of Hematology(ASH) Meeting’ in Orlando on 7^th of December, Professor Jae-yong Kwak of Chonbuk National University Hospital(hematology-oncology) and Professor Sung-eun L...